Lysergide tartrate (LSD) · DT120
Small molecule
Also known as DT120
Evidence outlook · lead readout
NCT06809595 · Generalized Anxiety Disorder
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT06809595: Panorama was a randomized, triple-masked, placebo-controlled Phase 3 in 245 participants in generalized anxiety disorder. Its primary endpoint, HAM-A change, is a validated clinical scale and was met (p<0.0001) according to the company's topline release. The sources read give no power calculation, so the grade is moderate.
Also in development:Major Depressive Disorder · Phase 3Attention Deficit Hyperactivity Disorder · Phase 2
Company guidance: regulatory filing expected first half of 2027 (Definium Therapeutics, 9 Nov 2026). “On track for DT120 ODT NDA filing in first half of 2027” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06741228 NCT06741228 · Generalized Anxiety Disorder Voyage was a randomized, triple-masked, placebo-controlled Phase 3 in 214 participants in generalized anxiety disorder. Its primary endpoint, HAM-A change, is a validated clinical scale and was met (p<0.0001) according to the company's topline release. The sources read give no power calculation, so the grade is moderate. Registry: NCT06741228 | 3 | Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12 (Baseline to Week 12) 2026-07-15 | Primary endpoint, HAM-A change: -11.6 vs -6.2 with placebo, LS mean difference -5.4 points (p<0.0001) (Definium, 2026-08-12). | Partial signal | link ↗ |
View 2 more trials
NCT06809595 NCT06809595 · Generalized Anxiety Disorder Panorama was a randomized, triple-masked, placebo-controlled Phase 3 in 245 participants in generalized anxiety disorder. Its primary endpoint, HAM-A change, is a validated clinical scale and was met (p<0.0001) according to the company's topline release. The sources read give no power calculation, so the grade is moderate. Registry: NCT06809595 | 3 | Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12 (Baseline to Week 12) 2026-08-13 | Primary endpoint, HAM-A change at week 12 (100 µg): -9.8 vs -4.7 with placebo, LS mean difference -5.1 points (p<0.0001) (Definium, 2026-09-14). | Partial signal | link ↗ |
NCT05407064 NCT05407064 · Generalized Anxiety Disorder Registry: NCT05407064 | 2 | Dose Response (4 weeks) 2023-10-06 | Dose Response (4 weeks): Arm 1- Placebo — Mean Change from Baseline to Week 4 in HAM-A total score Model Averaging Method: -14.23 units on a scale (95% CI -17.83 to -10.63); Mean Difference in HAM-A total score from Placebo: 0 units on a scale (95% CI 0 to 0) | Arm 2- 25 μg MM-120 (LSD D-Tartrate) — Mean Change from Baseline to Week 4 in HAM-A total score Model Averaging Method: -15.35 units on a scale (95% CI -17.62 to -13.09); Mean Difference in HAM-A total score from Placebo: -1.24 units on a scale (95% CI -6.01 to 3.53) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) — Mean Change from Baseline to Week 4 in HAM-A total score Model Averaging Method: -16.05 units on a scale (95% CI -19.4 to -12.71); Mean Difference in HAM-A total score from Placebo: -1.82 units on a scale (95% CI -7.65 to 4) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) — Mean Change from Baseline to Week 4 in HAM-A total score Model Averaging Method: -19.22 units on a scale (95% CI -21.73 to -16.7); Mean Difference in HAM-A total score from Placebo: -5.02 units on a scale (95% CI -9.6 to -0.44) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) — Mean Change from Baseline to Week 4 in HAM-A total score Model Averaging Method: -20.09 units on a scale (95% CI -22.87 to -17.31); Mean Difference in HAM-A total score from Placebo: -5.95 units on a scale (95% CI -9.84 to -2.06) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other 5-HT2A receptor drugs
Deupsilocin, Psilocybin (COMP360), BPL-003 (mebufotenin benzoate), Bretisilocin, Mebufotenin (5-MeO-DMT) and 2 more. Compare all 8 5-HT2A receptor drugs
7 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Attention Deficit Hyperactivity Disorder: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lysergide Tartrate (LSD) (DT120): this drug | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Centanafadine (Simtriyo) | Approved | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint | |
| Viloxazine (Qelbree) | Approved | Small molecule | norepinephrine transporter | Reliable signal | NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91) NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52) | |
| Solriamfetol (Sunosi) | Phase 3 | Small molecule | Dopamine/norepinephrine transporter | not yet graded | No reviewed efficacy summary in this indication | |
| PDC-1421 | Phase 2 | Botanical | Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow DT120 (Lysergide tartrate (LSD)) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent